The difficulty I see here is that it took the yeast not very long to mutate a beneficial effect, but it could just as quickly mutate away from that and even mutate something harmful.
The biggest cost factor for classical pharma is QA. Both in the form of certifications before release and in the form of regular QA during production.
So skipping QA can of course bring the cost down massively, but with the cost of making a potentially very dangerous product.